Buhisan, Mark Rheo C.
HRN: 21-40-73 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/25/2022
CEFUROXIME 750MG (VIAL)
05/25/2022
05/31/2022
IV
500mg
Q8h
PCAP-C
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes